DBV Technologies | DBVT - Assets


DBV Technologies reported $110.49M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Amarin USD 659.81M 10.31M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
DBV Technologies USD 110.49M 32.93M Sep/2025
Halozyme Therapeutics USD 2.22B 167.33M Sep/2025
Incyte USD 6.33B 509M Sep/2025
Insmed USD 2.36B 119.12M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
PTC Therapeutics USD 2.64B 9.54M Sep/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Ultragenyx Pharmaceutical USD 1.19B 115.82M Sep/2025
United Therapeutics USD 7.35B 556.9M Sep/2025